PET-detected nodal upstaging predicts larger treatment volumes in esophageal cancer radiotherapy

PET-detected nodal upstaging was associated with >10% PTV expansion in 48% versus 17% of patients, accompanied by increased lung exposure.

KEY POINTS

  • This retrospective single-center study included 50 consecutive patients with esophageal cancer undergoing CT- and FDG-PET/CT-based radiotherapy planning between 2018 and 2022, with 49 evaluable for nodal upstaging. Most patients had squamous cell carcinoma (88%), and treatment consisted of definitive or neoadjuvant VMAT with prescriptions ranging from 41.4 to 50 Gy.
  • Separate target volumes were generated using contrast-enhanced CT alone and subsequently incorporating PET/CT information, with CT contours finalized before PET review. PET-positive nodal stations were incorporated into the clinical target volume when not already covered, followed by a uniform 7-mm CTV-to-PTV expansion. Clinically significant planning impact was prospectively defined for this analysis as a >10% increase in PTV volume.
  • PET-detected nodal upstaging occurred in 25 of 49 patients (51.0%), while 16 of 49 (32.7%) experienced PTV expansion greater than 10%. Among patients with nodal upstaging, 12/25 (48.0%) exceeded this threshold, compared with 4/24 (16.7%) without upstaging, an absolute difference of 31.3 percentage points (95% CI 6.7–55.9; p=0.032).
  • Nodal upstaging remained associated with significant PTV expansion after adjustment for tumor length (OR 4.38, 95% CI 1.12–17.10; p=0.033). Median percentage PTV change was 9.49% with nodal upstaging versus 0.31% without (p<0.001), with individual expansions reaching 64.71%. The parsimonious prediction model achieved an AUC of 0.725, with a bootstrap mean AUC of 0.733.
  • PET identified previously unrecognized nodal involvement across multiple anatomical compartments. Newly PET-positive stations most frequently included hilar nodes in 9/49 patients (18.4%), carinal/subcarinal nodes in 7/49 (14.3%), and tracheal/paratracheal nodes in 6/49 (12.2%). PET also reclassified some morphologically suspicious CT-positive stations as metabolically negative, demonstrating that its influence on target delineation was bidirectional.
  • Increased target volume was accompanied by a measurable lung dose penalty. Among patients with >10% PTV expansion, median changes from CT-based to PET-based plans were +2.13 Gy in mean lung dose, +8.13 percentage points in lung V5, and +5.93 points in lung V20, compared with +0.05 Gy, −0.16 points, and +0.24 points, respectively, in patients without significant expansion (all between-group p<0.001).
  • The primary binary finding was sensitive to one patient's CT contours being reconstructed after loss of the original planning data. Excluding that patient reduced statistical significance to p=0.060, despite a similar association magnitude; the 10% PTV threshold was not externally validated, respiratory motion was not assessed using 4D-CT, and the study did not evaluate whether PET-guided expansion improved disease control or clinical toxicity.

CLINICAL TAKEAWAY

FDG-PET/CT can materially alter esophageal radiotherapy target volumes by identifying nodal disease not apparent on anatomical imaging, with consequential increases in lung exposure. These results reinforce the importance of integrating metabolic staging into treatment planning while reassessing OAR constraints after target expansion, but the specific 10% threshold and its relationship to clinical outcomes require prospective validation.

SOURCE

Strahlentherapie und Onkologie

Browse more research Suggest a correction